Skip to main content
ACRS
NASDAQ Life Sciences

Aclaris Q3 10-Q: $204.6M Cash, $59.8M Nine-Month Loss, $116M Raised Via ATM

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.61
Mkt Cap
$559.494M
52W Low
$2.1
52W High
$6.6
52W Position info
72% above low
Off High info
45% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ACRS sits 72% above its 52-week low of $2.1.

Summary

Aclaris closed Q3 with $204.6 million in cash and securities after raising $116.2 million net through its ATM during 2026, enough to fund its clinical programs despite a nine-month net loss of $59.8 million and a share count that rose from 120.5 million to 150.8 million.


Key Events · Earnings and Guidance · ACRS

  • Q3 Loss Widens on Clinical Spend

    Net loss for Q3 2026 was $18.5 million ($0.12 per share), versus $14.6 million a year earlier; the nine-month loss reached $59.8 million versus $45.1 million.

  • Cash Position Grows to $204.6M

    Cash, cash equivalents and marketable securities totaled $204.6 million at September 30, 2026, up from $147.7 million at December 31, 2025; management states this funds operations for more than 12 months.

  • ATM Raises $116.2M Net in 2026

    At-the-market sales totaled 18.4 million shares for $59.8 million gross in March, 7.3 million shares for $40.2 million in July and 3.6 million shares for $20.0 million in September, netting $116.2 million.

  • October Offering Adds $46.7M Net

    The October 2026 offering closed with 7,785,714 shares at $3.50 and pre-funded warrants for 6,500,000 shares at $3.49999 per warrant, for $50.0 million gross and $46.7 million net.


Analysis · ACRS · Life Sciences

The balance sheet is the headline: cash and marketable securities stood at $204.6 million on September 30, up from $147.7 million at year-end, after the company pulled in $116.2 million net from at-the-market share sales during 2026 and another $46.7 million net from the October offering. That funding carries the bosakitug Phase 2 atopic dermatitis readout expected in Q4 2026 and the ATI-052 Phase 2b in eosinophilic esophagitis planned for early 2027 without a near-term financing. Dilution is the cost: shares outstanding climbed from 120.5 million to 150.8 million in nine months, and the loss widened to $59.8 million from $45.1 million as ATI-052 and ATI-9494 development spending ramped. No going-concern language appears — management says cash covers more than 12 months.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACRS was trading at $3.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $559.5M. The 52-week trading range was $2.10 to $6.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACRS - Latest Insights

ACRS
Nov 16, 2026, 6:03 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.28
Real-time Price: $3.44 info
Change: +$0.160 (+5%) info
Market Cap: $545.626M info
ACRS
Nov 16, 2026, 3:28 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.76
Real-time Price: $3.44 info
Change: -$0.320 (-9%) info
Market Cap: $545.626M info
ACRS
Nov 05, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.44 info
Change: -$0.170 (-5%) info
Market Cap: $545.626M info
ACRS
Oct 27, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $3.44 info
Change: -$0.280 (-8%) info
Market Cap: $545.626M info
ACRS
Oct 27, 2026, 6:43 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.63
Real-time Price: $3.44 info
Change: -$0.190 (-5%) info
Market Cap: $545.626M info